In the wake of the increase in Current Liabilities in the fourth quarter 2025, Quick Ratio fell to 10.87 below Genenta Science S P A average.

Within Biotechnology & Pharmaceuticals industry 16 other companies have achieved higher Quick Ratio than Genenta Science S P A in fourth quarter 2025. While Quick Ratio total ranking has improved so far during the Q4 2025 to 225, from total ranking in the third quarter 2025 at 498.

Explain Quick Ratio?
How much Cash & cash equivalents GNTA�s has?
What are GNTA�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/GNTA/financial-strength

https://api.csimarket.com/api/v1/companies/GNTA/fundamentals

https://api.csimarket.com/api/v1/companies/GNTA/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

GNTA Quick Ratio	(Dec 31 2025) Q4	0 Q3	0 Q2	0 Q1	(Dec 31 2024) Q4
Y / Y Current Liabilities Change	-7.74 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	200.65 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	10.87	Subscribe	Subscribe	Subscribe	Subscribe
GNTA's Total Ranking	# 225	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	53.05 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	25.18 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio fourth quarter 2025 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 17
Healthcare Sector	# 87
Overall Market	# 225

Quick Ratio Statistics
High	Average	Low
38.09	17.51	6.03
(Dec 31 2021)		(Dec 31 2024)

Financial Statements
Genenta Science S P A 's Current Liabilities	$ 4 Millions	Visit GNTA's Balance sheet
Genenta Science S P A 's Cash & cash equivalent	$ 39 Millions	Visit GNTA's Balance sheet
Source of GNTA's Sales		Visit GNTA's Sales by Geography

Cumulative Genenta Science S P A 's Quick Ratio

GNTA's Quick Ratio for the trailling 12 Months

GNTA Quick Ratio	(Dec 31 2025) 12 Months	0 12 Months	0 12 Months	0 12 Months	(Dec 31 2024) 12 Months
Y / Y Current Liabilities TTM Growth	-2.21 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	140.82 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	12.47	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 660	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-2.76 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	24.45 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to GNTA Financial Strength Comparisons >> Go to Compare GNTA Quick Ratio to its Competitors

On the trailing twelve months basis GNTA Cash & cash equivalent more than doubled by 200.65 % in Q4 2025 year on year, while Current Liabilities soared to $4 millions, this led to increase in in Genenta Science S P A 's Quick Ratio to 12.47, above GNTA average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 156 other companies have achieved higher Quick Ratio than Genenta Science S P A . While Quick Ratio overall ranking has improved so far to 2744, from total ranking during the twelve months ending third quarter 2025 at 3354.

Explain Quick Ratio?
How much Cash & cash equivalents GNTA�s has?
What are GNTA�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 157
Healthcare Sector	# 976
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
13.65	5.14	2.13
(Dec 31 2022)		(Dec 31 2023)

Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Dec 31 2025 MRQ Cash & cash equivalent	Dec 31 2025 MRQ Current Liabilities
Palisade Bio Inc	28.77	$ 133.385 Millions	$ 4.636 Millions
Tectonic Therapeutic Inc	26.26	$ 253.798 Millions	$ 9.666 Millions
Apogee Therapeutics Inc	26.17	$ 730.192 Millions	$ 27.906 Millions
Cg Oncology Inc	24.07	$ 742.155 Millions	$ 30.836 Millions
Anavex Life Sciences Corp	23.67	$ 131.749 Millions	$ 5.566 Millions
Protara Therapeutics Inc	20.72	$ 200.909 Millions	$ 9.697 Millions
Leonabio Inc	18.50	$ 176.631 Millions	$ 9.550 Millions
Hemab Therapeutics Holdings Inc	18.49	$ 185.485 Millions	$ 10.030 Millions
Vor Biopharma Inc	18.29	$ 455.208 Millions	$ 24.891 Millions
Kyverna Therapeutics Inc	18.26	$ 279.253 Millions	$ 15.296 Millions
Kymera Therapeutics Inc	18.23	$ 848.276 Millions	$ 46.531 Millions
Maze Therapeutics Inc	15.16	$ 341.917 Millions	$ 22.556 Millions
Immunovant Inc	15.01	$ 994.525 Millions	$ 66.257 Millions
Compass Therapeutics Inc	14.96	$ 208.906 Millions	$ 13.968 Millions
Candel Therapeutics Inc	14.00	$ 119.731 Millions	$ 8.552 Millions
In8bio Inc	13.95	$ 27.092 Millions	$ 1.942 Millions
Crispr Therapeutics Ag	13.25	$ 1,975.828 Millions	$ 149.120 Millions
Tscan Therapeutics Inc	13.22	$ 152.406 Millions	$ 11.528 Millions
Eikon Therapeutics Inc	13.15	$ 335.975 Millions	$ 25.549 Millions
Precision Biosciences Inc	12.97	$ 115.585 Millions	$ 8.913 Millions
Beam Therapeutics Inc	12.85	$ 1,245.210 Millions	$ 96.935 Millions
Vaxcyte Inc	12.49	$ 1,560.959 Millions	$ 124.972 Millions
Kalaris Therapeutics Inc	12.15	$ 117.982 Millions	$ 9.714 Millions
Imagenebio Inc	12.05	$ 135.349 Millions	$ 11.234 Millions
Taysha Gene Therapies Inc	12.04	$ 319.767 Millions	$ 26.552 Millions
Engene Therapeutics Inc	11.21	$ 275.948 Millions	$ 24.609 Millions
Genenta Science S p a	10.87	$ 39.465 Millions	$ 3.630 Millions
Cullinan Therapeutics Inc	10.22	$ 377.896 Millions	$ 36.961 Millions
X4 Pharmaceuticals Inc	9.82	$ 252.998 Millions	$ 25.757 Millions
4d Molecular Therapeutics Inc	9.15	$ 402.655 Millions	$ 43.985 Millions

Date modified: 2026-10-05T11:03:39+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.